Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LPL | P06858 | 1/20 | 0.32 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.32 |
| ▸ | PFKFB3 | Q16875 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | TTR | P02766 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31394352 | 1.00 | PIK3CB (0.38) | PIK3CBMAPTENPP2CA2LPL | |
| SCHEMBL2251360 | 0.77 | DYRK1A (0.47) | MAPTENPP2DYRK1ATTRPRKCI | |
| SCHEMBL7924961 | 0.74 | CYP1A2 (0.42) | PIK3CBMAPTGRIN2BDYRK1APRKCI | |
| SCHEMBL19949854 | 0.74 | — | — | |
| SCHEMBL31367922 | 0.74 | — | — | |
| SCHEMBL23346665 | 0.73 | PIK3CB (0.49) | PIK3CBMAPTGRIN2BGRIN1DYRK1A | |
| SCHEMBL19152184 | 0.73 | HPGD (0.44) | PIK3CBMAPTGRIN2BGRIN1 | |
| SCHEMBL19630106 | 0.73 | PIK3CB (0.41) | PIK3CBGRIN2BGRIN1 | |
| SCHEMBL2371256 | 0.73 | HSD17B10 (0.44) | PIK3CBMAPTGRIN2BGRIN1DYRK1A | |
| SCHEMBL2694345 | 0.72 | APP (0.40) | PIK3CBMAPTCA2PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-05-31 | — | — | US | disclosed |
| EP-3294729-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2018-03-21 | — | — | EP | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
| WO-2016180536-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | SELVITA S.A. (PL) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148429-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES | BRCA1, NQO2, NQO1 | PIK3CB 1653/4885MAPT 4457/4885ENPP2 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.